Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.82 |
| ▸ | HTT | P42858 | 7/20 | 0.82 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | BCL6 | P41182 | 1/20 | 0.69 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.64 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.63 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.63 |
| ▸ | XBP1 | P17861 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15426114 | 0.78 | MAPT (0.70) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL13391186 | 0.73 | MEN1 (0.61) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL15426116 | 0.71 | MAPT (0.69) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL13401763 | 0.69 | MAPT (0.65) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL2483774 | 0.69 | MEN1 (0.81) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL297980 | 0.68 | IDO1 (1.00) | MAPTALDH1A1HTTNPSR1MEN1 | |
| SCHEMBL5281834 | 0.68 | MAPT (0.74) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL17788961 | 0.67 | GSTM2 (0.90) | HTTBCL6BCORMEN1KMT2A | |
| SCHEMBL5281823 | 0.67 | MAPT (0.73) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 | |
| SCHEMBL9820257 | 0.67 | BCL6 (0.53) | MAPTALDH1A1HTTNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-9073896-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | MAPT 3367/4885ALDH1A1 2436/4885HTT 1828/4885 |
| US-20140113891-A1 | Compounds that inhibit human DNA ligases and methods of treating cancer | LIG1, LIG4, LIG3 | MAPT 3367/4885ALDH1A1 2436/4885HTT 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.